Professional or Occupational Group
Federal Judge Dismisses $6.4 Billion Lawsuit Against Bristol Myers Squibb Over Celgene Acquisition
Bristol Myers Squibb (BMS), Celgene Acquisition, $6.4 Billion Lawsuit, Contingent Value Rights (CVR), Federal Judge Ruling, Pharmaceutical Industry, Legal Dispute
UK Regulator Approves Pharming’s Joenja for Rare Immune Disorder APDS, Leveraging FDA Review
Joenja, leniolisib, APDS, MHRA approval, FDA review, rare immune disorder, Pharming
Headlands Research Expands with New Clinical Trial Site in El Paso, Texas
Headlands Research, clinical trial site, El Paso, Texas, diversity in clinical research, clinical trials, medical research
Navigating Complex Regulatory Landscapes: The Importance of External Support for Biotech Sponsors in IRB, IBC, DMCs, and EACs
Biotech sponsors, IRB (Institutional Review Board), IBC (Institutional Biosafety Committee), DMCs (Data Monitoring Committees), EACs (Ethics Advisory Committees), Regulatory compliance, Clinical trials, Gene therapy research, Risk management
Enhancing Flu Vaccine Uptake in the Post-Pandemic Era: Strategies and Insights
flu vaccine uptake, post-pandemic era, vaccine hesitancy, public health strategies, healthcare providers, influenza vaccination
House Oversight Chair Demands PBM Executives Correct False Testimonies
PBM Executives, False Testimonies, House Oversight Chair, James Comer, Pharmacy Benefit Managers, Congressional Hearing
US Lawmakers Demand FDA Probe into Clinical Trials Linked to China’s Military
FDA investigation, clinical trials, China’s military, US lawmakers, bipartisan scrutiny
Embracing Agility: Critical for the Role of QARA Professional
QARA Professional, Agility, Quality Assurance, Regulatory Affairs, Market Access, Innovative Therapeutic Solutions, AI, Technology, Regulatory Strategy, Leadership, Communication, Diversity, Inclusion.
FDA Approves First Engineered T Cell Therapy for Solid Tumors, Expands GSK’s Jemperli
FDA approval, engineered T cell therapy, solid tumors, GSK’s Jemperli, dostarlimab-gxly, afamitresgene autoleucel, Tecelra, endometrial cancer, synovial sarcoma
MBX Secures $63.5M in Funding Ahead of Clinical Readouts
MBX, clinical readouts, funding, engineered peptide therapeutics, hypoparathyroidism, Phase II trial